Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer — Stella

Recruiting

Back to Endometrial Carcinoma trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(1 site)

China

Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing Municipality

Key details

Phase

Safety & dosing

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Enrollment target

~117 participants

Started

May 2024

Primary completion

June 2026

Age range

18 Years and older

Sex

Female only

Last updated May 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov